Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics and Pharmacogenomics in Oncology Therapeutic Antibody Development

1 Oct 2005

Abstract excerpt

Pharmacogenetics and pharmacogenomics are keys to the success of personalized medicine, prescribing drugs based on a patient's individual genetic and biological profile. In this review, we will focus on the application of pharmacogenetics and pharmacogenomics in developing monoclonal antibody (MAb) therapeutics in oncology. The significance of pharmacogenomics in MAb therapeutics is highlighted by the association...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16235569
DOI: 10.2144/000112043

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics and Pharmacogenomics in Oncology Therapeutic Antibody DevelopmentPMID 16235569Read ↗

Pharmacogenomics in Tailoring First-Line Therapy for Breast Cancer: PharmGKB Database InsightsSemantic proximity Read ↗

Pharmacogenetics of EGFR and VEGF inhibition.Semantic proximity Read ↗

Clinical pharmacogenetics in oncology: the paradigm of molecular targeted therapies.Semantic proximity Read ↗

Pharmacogenetic Predictors of Response.Semantic proximity Read ↗

Impact of Human Genetic Variation Underlying Resistance to Antigen-Specific ImmunotherapySemantic proximity Read ↗

Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas.Semantic proximity Read ↗

Computational Engineering of a Therapeutic Antibody to Inhibit Multiple Mutants of HER2 Without Compromising Inhibition of the Canonical HER2Semantic proximity Read ↗

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancerSemantic proximity Read ↗

Pharmacogenetics of breast cancer therapies.Semantic proximity Read ↗

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.Semantic proximity Read ↗

Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy.Semantic proximity Read ↗

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.